Whether RWE can replace or only supplement an RCT from scientific-advice

Situation

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — scientific-advice briefing book — after a DSMB note on an imbalance that is not yet a signal. If scientific-advice briefing book cannot support RWE can replace or, the honest Pharma & Life Sciences output is hold.

Decision

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using scientific-advice briefing book after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• Authorize RWE can replace now; scientific-advice briefing book already has the discriminator after a DSMB note on an imbalance that is not yet a signal.
• Keep Only supplement an RCT in force until scientific-advice briefing book is completed after a DSMB note on an imbalance that is not yet a signal for pediatric-plan strategist.
• Treat scientific-advice briefing book as RWE can replace because both readings appear after a DSMB note on an imbalance that is not yet a signal.
• Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the page RWE can replace or turns on in scientific-advice briefing book.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move RWE can replace or for pediatric-plan strategist.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after a DSMB note on an imbalance that is not yet a signal). The follow-on FDA Response and Labeling action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.